The problem of renal function monitoring in patients treated with the novel antiretroviral drugs (Q39203030)

9 September 2017

The problem of renal function monitoring in patients treated with the novel antiretroviral drugs (English)

1 reference

9 September 2017

anti-retroviral agent

0 references

Paolo Bonfanti

6

0 references

Paolo Maggi

Paolo Maggi

1

0 references

Stefano Rusconi

Stefano Rusconi

3

0 references

Antonio Di Biagio

Antonio Di Biagio

4

0 references

Leonardo Calza

7

Leonardo Calza

1 reference

9 September 2017

8

Paola Corsi

1 reference

9 September 2017

10

Cristina Mussini

1 reference

9 September 2017

Vincenzo Montinaro

2

1 reference

PubMed ID

24947532

9 September 2017

Rita Bellagamba

5

1 reference

PubMed ID

24947532

9 September 2017

Francesco Montella

9

1 reference

9 September 2017

1 May 2014

1 reference

9 September 2017

1 reference

9 September 2017

15

1 reference

9 September 2017

3

1 reference

9 September 2017

87-91

1 reference

Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

9 September 2017

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Cystatin C in HIV-infected patients: promising but not yet ready for prime time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

HIV viremia and changes in kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Association between albuminuria and proteinuria in the general population: the AusDiab Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

The use of biomarkers for assessing HAART-associated renal toxicity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Approach to the hypophosphatemic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1503-87

21 January 2018

Identifiers

DOI

10.1310/HCT1503-87

1 reference

9 September 2017

1 reference

PubMed ID

24947532